Intraindividual Blood Pressure Responses to Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade
Version of Record online: 25 MAY 2007
The Journal of Clinical Hypertension
Volume 7, Issue 1, pages 18–23, January 2005
How to Cite
Stergiou, MD, G. S., Roussias, L. G. and Mountokalakis, T. D. (2005), Intraindividual Blood Pressure Responses to Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade. The Journal of Clinical Hypertension, 7: 18–23. doi: 10.1111/j.1524-6175.2005.03859.x
- Issue online: 25 MAY 2007
- Version of Record online: 25 MAY 2007
- Manuscript received July 13, 2004;revised September 15, 2004;accepted October 25, 2004
This study aims to test the hypothesis that in some hypertensive subjects the blood pressure (BP) response to angiotensin-converting enzyme inhibition differs from that to angiotensin receptor blockade (ARB); a responder to angiotensin-converting enzyme inhibition may not respond to ARB or the opposite. A randomized, open-label, crossover, comparative trial of lisinopril 20 mg compared with telmisartan 80 mg (5 weeks per treatment period) was conducted in 32 untreated hypertensives using 24-hour ambulatory BP monitoring. Subjects were classified as “responders” and “nonresponders” using an arbitrary threshold of ambulatory BP response (≥10 mm Hg systolic or ≥5 diastolic) or the median response achieved by each drug. No difference was detected between the drugs in their effect on ambulatory BP (mean difference 1.2±7.1/0.7±5.1 mm Hg, systolic/diastolic). Significant correlations were found between the antihypertensive responses to the two drugs (r=0.77, p<0.001). Using the arbitrary response criterion, there was a difference between the drugs in the responses in 28%/13% of subjects (9/4 patients) for systolic/diastolic BP (19%/25% using the median response criterion).
These data suggest that in some hypertensive patients the BP response to angiotensin-converting enzyme inhibition may fail to predict the response to ARB. It appears that there are differences in the antihypertensive action of angiotensin-converting enzyme inhibitors and ARBs that may be clinically important.